HER2 –Gastric Cancer FDA approvedPrint this page
Updated Test Information:
HER2 –Gastric Cancer FDA approved
Probes: HER2(17q12)/CEP 17 (17p11.2)
Disease(s): Gastric Cancer, gastroesophageal adenocarcinoma, Gastroesophageal junction (GEJ) cancer.
Tumor Formalin fixed paraffin embedded (FFPE) tissue blocks or
|Additional Processing Details||
ASCO/CAP 2018 Guidelines recommend fixation time between 6 and 72 hours for breast tissue; however, special ASCO/CAP guidelines have not been established for gastric cancer samples.
Transport to the testing lab at room temp is acceptable. Do not allow sample to overheat. Use cold pack for transport, making sure cold pack is not in direct contact with specimen
Complete the Incyte Diagnostics hematology requisition with the patient's demographics and relevant clinical history. Label the specimen containers with patient's full name, second unique identifier, and specimen site/source.
|Unacceptable Specimen Conditions||
Specimen containers without two (2) patient identifiers, specimens submitted on non-positively charged slides, paraffin blocks that have been overheated or frozen, specimens without a H&E slide, slides or paraffin blocks with no tissue remaining, Samples fixed in fixative other than 10% neutral buffered formalin.
Fluorescence in-Situ Hybridization (FISH)
3-5 working days from receipt
Clinical Significance: HER2, a member of the epidermal growth factor receptor family, is a transmembrane protein with tyrosine kinase activity. Gene amplification and protein overexpression of HER2 have been found in a variety of tumors. This test provides HER2 amplification status to aid in determining anti-HER2 targeted therapies for patients with gastric cancer. Scoring for HER2 is performed according to 2016 CAP/ASCP/ACSO consensus guidelines for gastric/gastroesophageal adenocarcinoma
Limitations: Use of fixatives other than 10% formalin, fixation times less than six hours or greater than 48 hours may not yield reliable results.
Results of the HER-2/neu FISH assay should always be used in conjunction with other information available from the clinical evaluation of the patient and other prognostic factors, such as tumor size, histologic grade, nodal status, patient's age, hormone receptor status, and other known risk factors.